U.S. Ebola Treatment Center Clinical Laboratory Support
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
http://jcm.asm.org/content/54/4/1031.full.pdfItem Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
Voir les documents
Titre
U.S. Ebola Treatment Center Clinical Laboratory Support
Sujet
Description
Fifty-five hospitals in the United States have been designated Ebola treatment centers (ETCs) by their state and local health authorities.
Date
2016-04-01
Type
Citer ce document
Jelden, K. C., P. C. Iwen, J. J. Herstein, P. D. Biddinger, C. S. Kraft, L. Saiman, P. W. Smith, A. L. Hewlett, S. G. Gibbs and J. J. Lowe (2016). "U.S. Ebola Treatment Center Clinical Laboratory Support." J Clin Microbiol 54(4): 1031-1035.
Résumé
Fifty-five hospitals in the United States have been designated Ebola treatment centers (ETCs) by their state and local health authorities. Designated ETCs must have appropriate plans to manage a patient with confirmed Ebola virus disease (EVD) for the full duration of illness and must have these plans assessed through a CDC site visit conducted by an interdisciplinary team of subject matter experts. This study determined the clinical laboratory capabilities of these ETCs. ETCs were electronically surveyed on clinical laboratory characteristics. Survey responses were returned from 47 ETCs (85%). Forty-one (87%) of the ETCs planned to provide some laboratory support (e.g., point-of-care [POC] testing) within the room of the isolated patient. Forty-four (94%) ETCs indicated that their hospital would also provide clinical laboratory support for patient care. Twenty-two (50%) of these ETC clinical laboratories had biosafety level 3 (BSL-3) containment. Of all respondents, 34 (72%) were supported by their jurisdictional public health laboratory (PHL), all of which had available BSL-3 laboratories. Overall, 40 of 44 (91%) ETCs reported BSL-3 laboratory support via their clinical laboratory and/or PHL. This survey provided a snapshot of the laboratory support for designated U.S. ETCs. ETCs have approached high-level isolation critical care with laboratory support in close proximity to the patient room and by distributing laboratory support among laboratory resources. Experts might review safety considerations for these laboratory testing/diagnostic activities that are novel in the context of biocontainment care.
Accessibilité
free online
Was this resource helpful?